This study investigates solid tumors. It looks at how an investigational medication works with other treatments for people with these tumors.
The study evaluates the safety and tolerability of the investigational medication. It focuses on understanding how well patients can handle the treatment.
- Who can participate: Participants should be between 18 and 75 years old with a confirmed diagnosis of advanced pancreatic cancer. An ECOG performance status of 0 or 1, measurable lesions, and provision of tumor tissue are required.
- Study details: Participants will receive a combination of the investigational medication with other therapies.